Published in J Rheumatol on February 01, 2010
Systemic and vascular inflammation in patients with moderate to severe psoriasis as measured by [18F]-fluorodeoxyglucose positron emission tomography-computed tomography (FDG-PET/CT): a pilot study. Arch Dermatol (2011) 1.88
Evaluation of spinal mobility measurements in predicting axial psoriatic arthritis. Clin Rheumatol (2011) 0.81
Enthesitis in seronegative spondyloarthropathies with special attention to the knee joint by MRI: a step forward toward understanding disease pathogenesis. Clin Rheumatol (2011) 0.76
2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) (2012) 12.07
A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. Am J Hum Genet (2006) 9.56
Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways. Nat Genet (2009) 9.45
A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1. Nat Genet (2010) 8.48
Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity. Nat Genet (2012) 4.13
Headache in systemic lupus erythematosus: results from a prospective, international inception cohort study. Arthritis Rheum (2013) 4.02
Exercise therapy after corticosteroid injection for moderate to severe shoulder pain: large pragmatic randomised trial. BMJ (2010) 3.56
Epidemiology of psoriatic arthritis in the population of the United States. J Am Acad Dermatol (2005) 3.04
Investigation of the cause of death in a gene-therapy trial. N Engl J Med (2009) 3.02
Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1). Ann Rheum Dis (2012) 3.00
Mutations in 15-hydroxyprostaglandin dehydrogenase cause primary hypertrophic osteoarthropathy. Nat Genet (2008) 2.88
Identification of multiple risk variants for ankylosing spondylitis through high-density genotyping of immune-related loci. Nat Genet (2013) 2.87
Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum (2005) 2.80
Genome-wide association analysis identifies three psoriasis susceptibility loci. Nat Genet (2010) 2.76
A prospective study of telomere length and the risk of skin cancer. J Invest Dermatol (2008) 2.75
Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum (2005) 2.71
Genome-wide association study identifies a psoriasis susceptibility locus at TRAF3IP2. Nat Genet (2010) 2.66
Use of tanning beds and incidence of skin cancer. J Clin Oncol (2012) 2.65
Patient perspectives on the impact of fibromyalgia. Patient Educ Couns (2008) 2.57
Topical calcineurin inhibitors for atopic dermatitis: balancing clinical benefit and possible risks. Arch Dermatol (2006) 2.56
Common variants at TRAF3IP2 are associated with susceptibility to psoriatic arthritis and psoriasis. Nat Genet (2010) 2.56
Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum (2009) 2.49
Development and assessment of users' satisfaction with the systemic lupus erythematosus disease activity index 2000 responder index-50 website. J Rheumatol (2012) 2.48
Indoor tanning and non-melanoma skin cancer: systematic review and meta-analysis. BMJ (2012) 2.43
Effect of umbilical cord milking in term and near term infants: randomized control trial. Am J Obstet Gynecol (2012) 2.33
National Psoriasis Foundation clinical consensus on disease severity. Arch Dermatol (2007) 2.29
Prevalence of the metabolic syndrome in psoriasis: results from the National Health and Nutrition Examination Survey, 2003-2006. Arch Dermatol (2010) 2.29
Genome-wide association study identifies novel loci predisposing to cutaneous melanoma. Hum Mol Genet (2011) 2.26
National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening. J Am Acad Dermatol (2008) 2.19
Comparative effectiveness of commonly used systemic treatments or phototherapy for moderate to severe plaque psoriasis in the clinical practice setting. Arch Dermatol (2012) 2.19
Impact of obesity and smoking on psoriasis presentation and management. Arch Dermatol (2005) 2.15
Single nucleotide polymorphisms in the MATP gene are associated with normal human pigmentation variation. Hum Mutat (2005) 2.15
The impact of accepting living kidney donors with mild hypertension or proteinuria on transplantation rates. Am J Kidney Dis (2006) 2.14
Assessment of patients with psoriatic arthritis: a review of currently available measures. Arthritis Rheum (2004) 2.14
The concept of axial spondyloarthritis: joint statement of the spondyloarthritis research and treatment network and the Assessment of SpondyloArthritis international Society in response to the US Food and Drug Administration's comments and concerns. Arthritis Rheumatol (2014) 2.14
Changing patterns in mortality and disease outcomes for patients with systemic lupus erythematosus. J Rheumatol (2008) 2.11
Repair of radiographic joint damage following treatment with etanercept in psoriatic arthritis is demonstrable by 3 radiographic methods. J Rheumatol (2011) 2.07
Pneumococcal vaccine response in psoriatic arthritis patients during treatment with etanercept. J Rheumatol (2004) 2.07
The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus. Arthritis Rheum (2010) 2.06
Difference in disease features between childhood-onset and adult-onset systemic lupus erythematosus. Arthritis Rheum (2008) 2.06
A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis. J Am Acad Dermatol (2004) 2.05
Teenage acne and cancer risk in US women: A prospective cohort study. Cancer (2015) 2.05
Relapsing leukocytoclastic vasculitis triggered by activity in a young woman. Arch Dermatol (2009) 2.02
Systematic microanatomical analysis of CXCL13 and CCL21 in situ production and progressive lymphoid organization in rheumatoid synovitis. Eur J Immunol (2005) 1.96
Systemic tumor necrosis factor alpha mediates an increase in peripheral CD11bhigh osteoclast precursors in tumor necrosis factor alpha-transgenic mice. Arthritis Rheum (2004) 1.94
Rare and common variants in CARD14, encoding an epidermal regulator of NF-kappaB, in psoriasis. Am J Hum Genet (2012) 1.88
Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Ann Rheum Dis (2014) 1.88
Evaluation of American Joint Committee on Cancer, International Union Against Cancer, and Brigham and Women's Hospital tumor staging for cutaneous squamous cell carcinoma. J Clin Oncol (2013) 1.83
Association between IL13 polymorphisms and psoriatic arthritis is modified by smoking. J Invest Dermatol (2009) 1.82
Obesity in early adulthood as a risk factor for psoriatic arthritis. Arch Dermatol (2010) 1.80
A delphi exercise to identify characteristic features of gout - opinions from patients and physicians, the first stage in developing new classification criteria. J Rheumatol (2013) 1.77
A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol (2003) 1.77
Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. Ann Rheum Dis (2013) 1.74
Factors predictive of recurrence and death from cutaneous squamous cell carcinoma: a 10-year, single-institution cohort study. JAMA Dermatol (2013) 1.73
Reappraisal of the effectiveness of methotrexate in psoriatic arthritis: results from a longitudinal observational cohort. J Rheumatol (2007) 1.73
Problems with the definition of axial and peripheral disease patterns in psoriatic arthritis. J Rheumatol (2005) 1.72
Is there an advantage over SF-36 with a quality of life measure that is specific to systemic lupus erythematosus? J Rheumatol (2011) 1.72
Systematic review of treatments for psoriatic arthritis: an evidence based approach and basis for treatment guidelines. J Rheumatol (2006) 1.70
Measuring dactylitis in clinical trials: which is the best instrument to use? J Rheumatol (2007) 1.69
Longitudinal assessment of synovial, lymph node, and bone volumes in inflammatory arthritis in mice by in vivo magnetic resonance imaging and microfocal computed tomography. Arthritis Rheum (2007) 1.68
Autoimmune, atopic, and mental health comorbid conditions associated with alopecia areata in the United States. JAMA Dermatol (2013) 1.66
Persistent proteinuria and dyslipidemia increase the risk of progressive chronic kidney disease in lupus erythematosus. Kidney Int (2011) 1.63
Anti-dsDNA antibody testing by Farr and ELISA techniques is not equivalent. J Rheumatol (2006) 1.62
Phenotypes of atopic dermatitis. J Dtsch Dermatol Ges (2010) 1.60
Consensus on a core set of domains for psoriatic arthritis. J Rheumatol (2007) 1.60
Seborrheic keratoses: a study comparing the standard cryosurgery with topical calcipotriene, topical tazarotene, and topical imiquimod. Int J Dermatol (2004) 1.59
Sunlight exposure, vitamin D, and risk of non-Hodgkin lymphoma in the Nurses' Health Study. Cancer Causes Control (2011) 1.58
Risk factors for development of coronary artery disease in women with systemic lupus erythematosus. J Rheumatol (2009) 1.58
Multiple Loci within the major histocompatibility complex confer risk of psoriasis. PLoS Genet (2009) 1.58
Serum autoantibodies that bind citrullinated fibrinogen are frequently found in patients with rheumatoid arthritis. J Rheumatol (2006) 1.54
Inhibition of lymphangiogenesis and lymphatic drainage via vascular endothelial growth factor receptor 3 blockade increases the severity of inflammation in a mouse model of chronic inflammatory arthritis. Arthritis Rheum (2009) 1.54
Axial psoriatic arthritis: update on a longterm prospective study. J Rheumatol (2009) 1.53
Recombinant human relaxin in the treatment of systemic sclerosis with diffuse cutaneous involvement: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum (2009) 1.53
Patient global assessment in psoriatic arthritis: a multicenter GRAPPA and OMERACT study. J Rheumatol (2011) 1.52
Limitations in screening instruments for psoriatic arthritis: a comparison of instruments in patients with psoriasis. J Rheumatol (2013) 1.52
The PASE questionnaire: pilot-testing a psoriatic arthritis screening and evaluation tool. J Am Acad Dermatol (2007) 1.52
Diffuse idiopathic skeletal hyperostosis in psoriatic arthritis. J Rheumatol (2013) 1.51
Genome-wide association study of tanning phenotype in a population of European ancestry. J Invest Dermatol (2009) 1.50
Etanercept in the treatment of adult patients with Still's disease. Arthritis Rheum (2002) 1.50
Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European/North American dermatology clinics. J Am Acad Dermatol (2013) 1.50
The composite DAS Score is impractical to use in daily practice: evidence that physicians use the objective component of the DAS in decision making. J Clin Rheumatol (2009) 1.50
Shorter telomeres associate with a reduced risk of melanoma development. Cancer Res (2011) 1.49